These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31107822)

  • 21. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
    van Dijk M; van Roon AM; Said MY; Bemelman FJ; Homan van der Heide JJ; de Fijter HW; de Vries APJ; Bakker SJL; Sanders JSF
    Transpl Int; 2018 Dec; 31(12):1380-1390. PubMed ID: 30106185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
    Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
    Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.
    Villamil FG; Gadano AC; Zingale F; Perez R; Gil O; Yantorno S; Mastai R; Cairo FO; Otero AB; Dong G; Lopez P;
    Liver Int; 2014 Nov; 34(10):1513-21. PubMed ID: 25453134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.
    Malvezzi P; Fischman C; Rigault G; Jacob MC; Raskovalova T; Jouve T; Janbon B; Rostaing L; Cravedi P
    Transpl Immunol; 2019 Oct; 56():101207. PubMed ID: 31071442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients.
    Leyking S; Budich K; van Bentum K; Thijssen S; Abdul-Khaliq H; Fliser D; Sester M; Sester U
    J Transl Med; 2015 Feb; 13():51. PubMed ID: 25885792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation.
    Bestard O; Cruzado JM; Lucia M; Crespo E; Casis L; Sawitzki B; Vogt K; Cantarell C; Torras J; Melilli E; Mast R; Martinez-Castelao A; Gomà M; Reinke P; Volk HD; Grinyó JM
    Kidney Int; 2013 Dec; 84(6):1226-36. PubMed ID: 23783240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive Drug Levels in Liver Transplant Recipients: Impact in Decision Making.
    Kourkoumpetis T; Levitsky J
    Semin Liver Dis; 2019 Nov; 39(4):414-421. PubMed ID: 31041787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired GATA3-dependent chromatin remodeling and Th2 cell differentiation leading to attenuated allergic airway inflammation in aging mice.
    Hasegawa A; Miki T; Hosokawa H; Hossain MB; Shimizu C; Hashimoto K; Kimura MY; Yamashita M; Nakayama T
    J Immunol; 2006 Feb; 176(4):2546-54. PubMed ID: 16456016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.
    Nikoueinejad H; Soleimani A; Mirshafiey A; Amirzargar A; Sarrafnejad A; Kamkar I; Einollahi B
    Exp Clin Transplant; 2013 Feb; 11(1):12-6. PubMed ID: 23387537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
    Mulgaonkar S; Kaufman DB
    Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of 3 Major Maintenance Immunosuppressive Protocols on Long-term Clinical Outcomes: Result of a Large Multicenter Italian Cohort Study Including 5635 Renal Transplant Recipients.
    Caletti C; Manuel Ferraro P; Corvo A; Tessari G; Sandrini S; Capelli I; Minetti E; Gesualdo L; Girolomoni G; Boschiero L; Lupo A; Zaza G
    Transplant Proc; 2019; 51(1):136-139. PubMed ID: 30655148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation.
    De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Filipponi F
    Best Pract Res Clin Gastroenterol; 2017 Apr; 31(2):199-209. PubMed ID: 28624108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Mammalian Target of Rapamycin Inhibitors for Pancreas Transplant Immunosuppression Is Associated With Improved Allograft Survival and Improved Early Patient Survival.
    Siskind EJ; Liu C; Collins DT; Emery E; Steen E; Tran E; Stodghill J; Piper J; Jonsson J; Ortiz J
    Pancreas; 2019; 48(5):644-651. PubMed ID: 31091210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of in vivo rapamycin treatment on de novo T-cell development in relation to induction of autoimmune-like immunopathology in the rat.
    Damoiseaux JG; Beijleveld LJ; Schuurman HJ; van Breda Vriesman PJ
    Transplantation; 1996 Oct; 62(7):994-1001. PubMed ID: 8878395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.
    Matz M; Fabritius K; Liu J; Lorkowski C; Brakemeier S; Unterwalder N; Dürr M; Mashreghi MF; Neumayer HH; Budde K
    Transpl Immunol; 2015 Nov; 33(3):176-84. PubMed ID: 26478531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.